MMV048 progresses to phase IIa as new formulation with 3x greater exposure identified

MMV048 is a novel antimalarial compound from the aminopyridine class, with important activity across the entire parasite lifecycle. The compound was researched by an international team led by Prof. Kelly Chibale from the University of Cape Town, South Africa and was the first new antimalarial medicine to enter phase I studies in Africa.

Read more in an interview with MMV's Dr Cristina Donini.

Updated July 2017